Dow Jones
33.309,51 +535,11 (+1,63%) Nasdaq
12.854,80 +360,88 (+2,89%) Nikkei 225
27.819,33 -180,63 (-0,65%) EUR/USD
1,0285 -0,0017 (-0,16%) BTC-EUR
23.895,03 +1.440,30 (+6,41%) CMC Crypto 200
578,43 +47,21 (+8,89%)
Merck & Co., Inc. (MRK)
Dopo ore:
- GlobeNewswire
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis
Phase 1b segment evaluated safety and tolerability of the combination Paves the way to expand and accelerate enrollment in the Phase 2 segment of the study ROCHESTER, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today reported positive interim safety data in the Phase Ib “safety run-in” segm
- GlobeNewswire
Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Home BancShares, Valley National, Kraton Corporation, and Acceleron Pharma on behalf of Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Home BancShares, Inc. (NASDAQ: HOMB), Valley National Bancorp (NASDAQ: VLY), Kraton Corporation (NYSE: KRA), and Acceleron Pharma, Inc. (NASDAQ: XLRN). Additional information about each potential action can be found at the link provided. Home Bancshares, Inc. (NASDAQ: HOMB) On September 28, 2021, Home BancShares announced that it ha
- GlobeNewswire
ACCELERON PHARMA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of XLRN and Encourages Investors to Contact the Firm
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Acceleron Pharma Inc. (NASDAQ: XLRN) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Merck & Co., Inc. (NYSE: MRK). Click here to learn more and participate in the action. On September 30, 2021, Acceleron announced that it had ent
